Belsomra is an insomnia treatment drug owned by Merck Sharp Dohme. The active ingredient in Belsomra is suvorexant. It received its first market authorization on 13th August, 2014 and is available in tablet form for oral administration. Belsomra holds a total of 2 patents, none of which have expired yet.
Belsomra generic is expected to be available after the expiration of its last patent on 29th May, 2033. This drug's patents, US10098892 and US7951797, cover solid dosage formulations of an orexin receptor antagonist and substituted diazepan orexin receptor antagonists respectively. The earlier patent expires on 20th November, 2029 but the availability of generic Belsomra is conditioned by the latter patent's expiration.
Belsomra is effectively used in the treatment of insomnia. suvorexant, the active ingredient in Belsomra, acts as an orexin receptor antagonist. By blocking the actions of orexin, a neurotransmitter that regulates arousal, wakefulness, and appetite, suvorexant promotes sleep and helps in managing insomnia symptoms.
Belsomra has 2 patents with none expired yet. The last patent for Belsomra is due to expire on 29th May, 2033, after which Belsomra generic may become available. Below is the details of the patents: